Prediction of brain atrophy using three drug scores in neuroasymptomatic HIV-infected patients with controlled viremia

ABSTRACT

BACKGROUND:

Despite potent antiretroviral therapy, HIV still causes brain damage. Better penetration into the CNS and efficient elimination of monocyte/macrophages reservoirs are two main characteristics of an antiretroviral drug that could prevent brain damage. The aim of our study was to assess efficacy of three antiretroviral drug scores to predict brain atrophy in HIV-infected patients.

METHODS:

A cross sectional study consisting of 56 HIV-infected patients with controlled viremia, who had no clinically evident neurocognitive impairment. All patients had MRI of the head. A typical T2 transversal slice was analyzed and ventricles-brain ratio (VBr) as an overall brain atrophy index was calculated. Three antiretroviral drug scores were used and correlated with VBr: 2008 and 2010 CNS penetration effectiveness scores (SCPE₂₀₀₈ and SCPE₂₀₁₀) and the recently established monocyte efficacy (SME) score. A p-value <0.05 was considered significant.

RESULTS:

SCPE₂₀₁₀ was significantly associated with VBr in both univariate (r = -0.285, p = 0.033) and multivariate (ß = -0.299, p = 0.016) regression models, while SCPE₂₀₀₈ was not (r = -0.141, p = 0.300 and ß = -0.156,p = 0.214). SME was associated with VBr in multivariate model only (r = -0.297, p = 0.111 andß = -0.406, p = 0.029). Age and reported duration of HIV infection were also significant predictors of overall brain atrophy in multivariate regression models.

CONCLUSIONS:

Although based on similar type of research, SCPE₂₀₁₀ is a superior drug score compared to SCPE₂₀₀₈. SME is an efficient drug score in determining brain damage. Both SCPE₂₀₁₀ and SME scores should be taken into account in preventive strategies of brain atrophy and neurocognitive impairment in HIV-infected patients.

Keywords:
CPE; Monocyte efficacy score; Brain atrophy; HAART; HIV

Introduction

Different neuropathological and neuroradiological studies have shown that HIV-infected patients have significant reduction of the brain parenchyma of both cortical^{1 and 2} and subcortical brain regions.^{3 and 4} Despite effective HIV treatment, brain tissue remains susceptible to the virus¹ as there is still detectable viral load in cerebrospinal fluid (CSF),⁵ brain volume loss^{6 7 and 8} and neurocognitive (NC) impairment.^{9 and 10} As shown in euroSIDA study, antiretroviral therapy significantly reduced the incidence of NC disorders caused by HIV,¹¹ but its prevalence is still high (15-40%).¹² Due to the blood-brain and the blood-CSF barriers, drug entry into the CNS is limited, which results in incomplete viral suppression in the CNS. That might be the reason why CNS acts as a reservoir for viral persistence and evolution of drug resistance, in which the virus acquire unique properties.^{13 and 14} Different penetration levels of antiretroviral drugs into the CNS have been quantified by CNS-penetration effectiveness score (CPE), established by Letendre et al.¹⁵ The score has 2008 (CPE₂₀₀₈) and 2010 (CPE₂₀₁₀) versions.^{15 and 16} Higher CPE means not only a better penetration efficacy into the CNS, but also a decline of new CNS events and even a decline in mortality rates.¹⁷ In contrast, a study by McManus et al.¹⁸ has not reached the same conclusion.

As viral reservoirs, circulating monocytes are considered to be responsible for chronic HIV infection in the brain. Activated monocytes traffic to the brain, where they become macrophages and produce inflammatory molecules. Increased inflammatory milieu results in damage of the brain tissue and eventually leads to NC impairment.^{19 20 21 22 and 23} Autopsy studies have shown increased number of macrophages in brain despite antiretroviral treatment.²⁴ Therefore, antiretroviral drugs that are effective in destroying viral reservoirs (monocytes and brain macrophages) should slow down brain atrophy and NC deterioration caused by HIV. Collecting in vitro data about effectiveness of antiretroviral drugs against activated monocytes/macrophages, Shikuma et al. established monocyte efficacy (ME) score of drugs and proved its efficacy in predicting NC impairment. ²⁵

To our knowledge, there is only one study in which these three drugs scores were compared and NC parameters were used as outcome.²⁵ There is no neuroimaging study in which ME score was validated and compared with CPE scores in assessing brain atrophy in HIV-infected patients.

The aim of our study was to compare recently established ME score with two CPE scores in terms of efficacy in predicting brain atrophy in HIV-infected patients. We also wanted to investigate other potential determinants of brain atrophy, such as age, nadir and current CD4⁺ T-cell count and durations of HIV infection and HAART.

Materials and methods

Study design and subjects

This cross-sectional study consisted of HIV-infected patients receiving care at the HIV/AIDS Center, Infectious Diseases Clinic, Clinical Center of Vojvodina in Novi Sad, Serbia. There were 81 patients, who had undergone MRI of the brain, which is around one-third of all registered patients. All MRIs were performed at the Diagnostic Imaging Center, Oncology Institute in Sremska Kamenica, Serbia from July 2011 to July 2014. Out of the 81 patients, 63 were on HAART and had plasma HIV RNA < 50 copies/mL for at least three months. Exclusion criteria were presence of focal brain changes on MRI, clinically evident NC impairment, co-infection with hepatitis C virus, and intravenous drug use. In a total of 56 patients who met all the above criteria (Suppl. 1) the International HIV Dementia Scale (IHDS) was applied as a neuropsychological screening test, established by Sacktor et al.²⁶ in which 0 is the worst and 12 is the best score. The study is a part of a larger project, which has been approved by the local ethics committee and informed consent was obtained from each patient.

Morphometry

For every included patient typical T2 transversal MRI slices were obtained in which lateral ventricles are most visible. Ventricular-brain ratio (VBr) was calculated by measuring lateral ventricles area and dividing by the brain area at the same level. This is a marker of overall brain atrophy and has already been used in studies on brain atrophy related to diseases including HIV.^{27 and 28}

Antiretroviral drugs and drug scoring systems

All patients were on highly active antiretroviral therapy (HAART) that consisted of two nucleoside reverse transcriptase inhibitors (NRTI) plus a protease inhibitor (PI) and/or non-nucleoside reverse transcriptase inhibitor (NNRTI). Three antiretroviral drug-scoring systems were used: 2008 and 2010 (CPE₂₀₀₈ and CPE₂₀₁₀) CPE score versions,^{15 and 16} and ME score.²⁵ All scores for antiretroviral regimens were calculated as a sum of the individual grades from the score. There are no published data on ME score of lopinavir/ritonavir (lpv/r) and darunavir. Therefore, for 26 (46.4%) patients, who were on lpv/r or darunavir, it was not possible to calculate SME values.

Statistical analyses

Data were evaluated and statistically processed using the software package IBM SPSS Statistics ver. 21. T-test for independent samples was used to assess differences in means of brain atrophy index between two groups. Pearson's coefficient was used for estimating correlation between brain atrophy index and parameters, such as age, nadir and current CD4⁺ T-cell count, duration of HIV, duration of HAART, and drug scores. Multivariate linear regression analyses were performed for assessing predictors of brain damage. All tests were two-tailed. A p < 0.05 was considered statistically significant.

Results

Mean age of patients in the study was 41 years, 89% were males. Demographic and virologic characteristics of the patients are shown in Table 1.

Table 1 -
Characteristics of patients. Data are shown as mean value (SD) or percentage.

	Total (n = 56)
Demographics
Age, years	41.1 (9.6)
Male gender	89%
Virology and therapy
Nadir CD4+ T-cell count, cells/mm3	186.0 (112.5)
Current CD4+ T-cell count, cells/mm3	472.5 (254.1)
HIV-positive status, months	69.9 (52.6)
Duration of therapy, months	39.4 (35.4)
Neuropsychological screening
IHDS, points	10.9 (1.0)
Brain morphometry
VBr, ×1000	84.2 (16.2)

• IHDS, International HIV Dementia Scale; VBr, ventricles-brain ratio.

Lamivudine was taken by 94.6%, abacavir by 67.9%, lpv/r by 44.6%, efavirenz by 42.9%, zidovudine by 30.4%, saquinavir/ritonavir by 10.7%, didanosine by 5.4%, nevirapine by 3.6%, and darunavir by 1.8% of patients (Fig. 1). Based on the presence of efavirenz in the regimen the patients were categorized into two groups. There were no significant differences in VBr (p = 0.926) and IHDS (p = 0.501) values between these two groups.

Fig. 1 -.
Antiretroviral drugs on use by study participants.

Mean values, SD, medians, IQR, minimal and maximal values of SCPE₂₀₀₈, SCPE₂₀₁₀, and SME scores are shown in Table 2. SME significantly correlated with SCPE₂₀₁₀(r = 0.546, p = 0.002), while the association between SME and SCPE₂₀₀₈ was not significant (r = 0.097,p = 0.609). Correlation between two the CPE versions (SCPE₂₀₀₈ and SCPE₂₀₁₀) was highly significant (r = 0.644, p < 0.001).

Table 2 -
Mean,median and measures of dispersion for three drug scores of patients in the study.

	Mean	SD	Median	IQR	Range
SCPE2008	2.16	0.45	2	2.0–2.5	1–3
SCPE2010	8.18	0.81	8	8–9	6–10
SME	152.80	35.52	153	153–170	73–200

• SCPE₂₀₁₀, CNS-penetration effectiveness score (version 2010) of the HAART regimen. SCPE₂₀₀₈, CNS-penetration effectiveness score (version 2008) of the HAART regimen. SME, monocyte efficacy score of the HAART regimen.

A linear regression model was built including each of the three drug scoring systems. The independent variables age, nadir and current CD4⁺ T-cell count, duration of HIV status and HAART therapy were included in each of the three regression models. The dependent variable in all models was VBr, a measure of brain atrophy. Results of these linear regression models are presented in Table 3. In univariate analyses age (r = 0.283, p = 0.035) and SCPE₂₀₁₀(r = -0.285, p = 0.033) were found to be significantly associated with brain atrophy. However, in multivariate analyses, both SCPE₂₀₁₀ and SME were significant predictors of brain atrophy (ß = -0.299, p = 0.016 and ß= -0.406, p = 0.029, respectively). SCPE₂₀₀₈ was neither significantly associated in univariate (r = -0.141,p = 0.300) nor in multivariate (ß = -0.156,p = 0.214) regression models. Age and duration of HIV-positive status were parameters that were significantly associated with brain atrophy in all three multivariate models ( Table 3).

Table 3 -
Linear regression models of three drug scoring systems with brain atrophy index (VBr) as a dependant variable.

Regression model	Independent variables	Univariate		Multivariate
		Correlation coefficient r	p	Regression coefficient ß	p	Model significance
SCPE2010	Age	0.283	0.035	0.390	0.003	p = 0.001
	Nadir CD4+ count	-0.113	0.406
	Current CD4+ count	-0.112	0.413
	Duration of HIV	0.235	0.082	0.291	0.022
	Duration of HAART	0.238	0.078
	SCPE2010	-0.285	0.033	-0.299	0.016
SCPE2008	Age	0.283	0.035	0.365	0.006	p = 0.008
	Nadir CD4+ count	-0.113	0.406
	Current CD4+ count	-0.112	0.413
	Duration of HIV	0.235	0.082	0.322	0.015
	Duration of HAART	0.238	0.078
	SCPE2008	-0.141	0.300	-0.156	0.214
SME	Age	0.283	0.035	0.348	0.045	p = 0.022
	Nadir CD4+ count	-0.113	0.406
	Current CD4+ count	-0.112	0.413
	Duration of HIV	0.235	0.082	0.377	0.043
	Duration of HAART	0.238	0.078
	SME	-0.297	0.111	-0.406	0.029

• SCPE₂₀₁₀, CNS-penetration effectiveness score (version 2010) of the HAART regimen. SCPE₂₀₀₈, CNS-penetration effectiveness score (version 2008) of the HAART regimen. SME, monocyte efficacy score of the HAART regimen.

Discussion

Numerous studies emphasized basal ganglia as the main region in which pathological effects of HIV take place in the CNS.^{4 and 6} Other studies showed that numerous cortical parts of the brain are damaged as well.^{29 and 30} Therefore, we have used VBr in our study, as an index of overall brain atrophy.

Our hypothesis was that the level of an antiretroviral drug in the CNS affects all steps in the neuropathogenesis chain. The first step includes inflammatory changes and neurological injury. It can be diagnosed with CSF markers and magnetic resonance spectroscopy. Atrophic changes occur in the second step, which can be evaluated with different neuroimaging methods. Structural damage further results in functional changes, the hallmark of the third step. These functional changes are observed as NC impairment and can be diagnosed using different neuropsychological tests. This integral approach has been proved with correlations between structural and functional variables in numerous studies,^{3 31 32 33 34 and 35} although there are also studies in which correlations were not shown.^{2 and 6}

One of the aims of our study was to compare two CPE scoring systems. The original SCPE₂₀₀₈ scoring system was based on clinical, pharmacological and chemical reports on antiretroviral drugs. In literature it was mostly indicated as a predictor of decreasing viral load in CSF^{15 and 36}; in neuropsychological studies the results are controversial.^{37 38 39 and 40} Imaging studies failed to prove SCPE₂₀₀₈ as a predictor of brain atrophy.^{4 7 and 8} Our results are in line with published reports as we found no significant association between SCPE₂₀₀₈ and VBr.

Although such an outcome was expected due to similar results previously reported, we hypothesized that SCPE₂₀₀₈ could be used to predict brain atrophy as it strongly correlates with SCPE₂₀₁₀. There are some possible reasons why the association is not shown:

-Sum of score values range is too narrow to show small differences. -CPE scale classifies drugs into only three categories, masking the differences among drugs in the same category.

On the contrary, a revised SCPE₂₀₁₀ was shown to be a good predictor of brain atrophy in both univariate and multivariate regression models. According to our results, it is expected that HAART regimens consisting of drugs with higher CPE₂₀₁₀ score have a protective effect on the brain tissue. The study by Ciccarelli et al., using NC performance as the outcome of interest, found results regarding SCPE₂₀₀₈ and SCPE₂₀₁₀ similar to our study. In their study SCPE₂₀₁₀ was emphasized as an improved predicting tool and a step forward compared to SCPE₂₀₀₈.⁴¹

There are very few neuroimaging studies that have examined SCPE₂₀₁₀. Ragin et al. conducted a neuroimaging study that showed association between brain atrophy and SCPE₂₀₁₀.²⁹ On the contrary, there are numerous studies in which NC performance was used as an outcome. Some studies have shown significant positive association, whereas others have not shown any association; furthermore, other studies have found even worse NC performance in patients who were on higher CPE drug regimens.^{31 41 42 and 43} Possible reasons for such discrepancy might be heterogonous cohorts regarding virological status and NC performance, HCV co-infection, and intravenous drug use among examined patients. Therefore, our cohort consisted only of neuroasymptomatic patients with HIV RNA < 50 copies/mL for at least three months. In order to reduce possible biases,^{44 and 45} we excluded HCV-HIV co-infected patients and intravenous drug users. Thus, a relatively homogenous sample was gathered representing the majority of our HIV-infected patients. Further longitudinal studies are needed to provide more data about exact influences of different variables on brain damage in these patients.

Possible neurotoxic effects of drugs with better penetration mentioned in several studies^{38 39 and 43} were not identified in our study. Efavirenz is the most often emphasized drug for its potential neurotoxicity.⁴⁶ However, in our study the relationship between the use of efavirenz and brain damage was not found.

Reported duration of HIV infection was significantly associated with brain atrophy. Results suggest that chronic infection of the CNS permanently damages brain tissue and causes brain atrophy, which has been documented in the literature.^{4 30 and 34} Hidden behind blood-brain barrier, relatively isolated environment increases the magnitude of damage. This finding suggests that patients should be always asked to provide, if possible, approximate date of infection with HIV, as this information might be important to estimate the extent of brain atrophy. The obvious problem of this parameter is its subjective nature. Often it is not possible to establish the approximate time of infection due to large number of partners and rarity of testing. As life expectancy of HIV-infected patients continuously increases, duration of HIV positive status also increases. According to our results, higher SCPE₂₀₁₀ might decrease effects of HIV duration in terms of brain atrophy.

Surprisingly, other HIV-related parameters, nadir and current CD4⁺ T-cell count, were not associated with VBr in our study. As for nadir CD4⁺T-cell count, results suggest that brain atrophy is affected more by the duration of immune compromise than its "depth". A failure to prove significant association between brain atrophy and current CD4⁺ T-cell count could be explained by individualized pattern of the immunological recovery in patients with undetectable viral load. Therefore its effect on the CNS is unpredictable. In literature, results in regard to effects of nadir and current CD4⁺ T-cell count on brain damage extent/NC impairment are controversial.^{1 6 29 and 47}

Duration of HAART was significantly associated with VBr in univariate analyses, similar to duration of HIV. Duration of HAART and duration of HIV are highly correlated with each other. For this reason it was necessary to select one of these two variables for multivariate analyses. As duration of HAART depends on the duration of HIV, we have included duration of HIV in multivariate analyses. A similar reasoning was used in the study by Kuper et al.⁸

As it was already mentioned, this is the first neuroimaging study, to our knowledge, in which association between a neuroimaging parameter and ME score is investigated. ME score is based on the hypothesis that suppression of HIV in the CNS actually means elimination of monocyte/macrophage reservoirs. Our results showed that SME is negatively associated with brain damage, suggesting that drugs that are effective in eliminating monocyte/macrophage reservoirs might protect brain tissue from injury. Similar results were shown in the study by Shikuma et al., in which ME score was associated with NC performance.²⁵

Effective SME drug regimens provide a completely new insight in prevention and treatment of the neurocognitive disorders caused by HIV. Elimination of reservoirs can start even before activated monocytes cross the blood-brain barrier and continues as brain macrophages enter into the CNS. In that sense, theoretically the ideal antiretroviral drug would be one that effectively destroys monocyte/macrophage reservoirs (in the periphery and in the CNS) and penetrates well into the CNS. So, combining both CPE and ME drug scores and integrating both qualities of a drug would be a step forward to a better understanding of pathological effects of HIV in the CNS and effects of HAART onto counteracting them. For establishing such a scoring system, larger cohorts and further investigation on pharmacokinetics and pharmacology of the drugs are needed.

In that sense, HAART regimens with high SME values could be more effective in clearing latent reservoirs not only in the CNS, but also throughout the whole body, as systemic clearing viral reservoirs would lead to eradication of the HIV.⁴⁸ To prove this, longitudinal studies are needed.

The main limitation of SME score is lack of known ME values for darunavir, atazanavir, and most importantly for lpv/r, although it is well known that this drug accumulates in monocytes.⁴⁹ Furtherin vitro analyses are needed to determine acute infection EC₅₀ values of these drugs and calculate their ME values.

Conclusions

Although the sample size might seem small and a follow-up would be a logical next step, the expensive and sophisticated imaging methods used in this study are not done routinely. Previous similar neuroimaging studies were done on a similar or even smaller sample. Although the marker used in this study was used in other studies on brain atrophy, there are now more accurate techniques to define brain volumes. Despite these limitations, our results suggest a few important conclusions. Firstly, SCPE₂₀₁₀ is a superior drug-scoring system compared to SCPE₂₀₀₈. Secondly, SME is an effective drug-scoring system in determining brain damage. Thirdly, both SCPE₂₀₁₀ and SME scores should be taken into account in preventing strategies of brain atrophy and NC impairment in HIV-infected patients.

Controversial results in literature concerning drug-scoring systems underscore the need for a new scoring system. One of the possibilities is to build a mathematical model combining SCPE₂₀₁₀ and SME scores, in which both important qualities of a drug (penetration in the CNS and elimination of reservoirs) would be presented. This would require larger longitudinal studies. The use of ME scoring system is limited due to missing values for some common HIV drugs, such as darunavir, atazanavir, and lpv/r.

Acknowledgements

We thank all the patients for their involvement in the study. We also thank the nursing staff at the HIV/AIDS Center of Infectious Diseases Clinic in Novi Sad and at the Diagnostic Imaging Center of Oncology Institute in Sremska Kamenica.

This study was supported by the Provincial Secretariat for Science and Technological Development, Government of the Autonomous Province of Vojvodina, Serbia (project 114-451-2255/2011-01).

References

• ¹
  Thompson PM, Dutton RA, Hayashi KM, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci U S A. 2005;102:15647-52.
• ²
  Towgood KJ, Pitkanen M, Kulasegaram R, et al. Mapping the brain in younger and older asymptomatic HIV-1 men: frontal volume changes in the absence of other cortical or diffusion tensor abnormalities. Cortex. 2012;48:230-41.
• ³
  Moore DJ, Masliah E, Rippeth JD, et al. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS. 2006;20:879-87.
• ⁴
  Becker JT, Sanders J, Madsen SK, et al. Subcortical brain atrophy persists even in HAART- regulated HIV disease. Brain Imaging Behav. 2011;5:77-85.
• ⁵
  Edén A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202:1819-25.
• ⁶
  Ances BM, Ortega M, Vaida F, Heaps J, Paul R. Independent effects of HIV, aging, and HAART on brain volumetric measures. J Acquir Immune Defic Syndr. 2012;59:469-77.
• ⁷
  Cohen RA, Harezlak J, Schifitto G, et al. Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol. 2010;16:25-32.
• ⁸
  Kuper M, Rabe K, Esser S, et al. Structural gray and white matter changes in patients with HIV. J Neurol. 2011;258:1066-75.
• ⁹
  Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21:1915-21.
• ¹⁰
  Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24:1243-50.
• ¹¹
  D&apos;Arminio Monforte A, Cinque P, Mocroft A, et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol. 2004;55:320-8.
• ¹²
  Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS. 2011;25:561-75.
• ¹³
  Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50:773-8.
• ¹⁴
  Churchill M, Nath A. Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS. 2013;8: 165-9.
• ¹⁵
  Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS penetration- effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70.
• ¹⁶
  Letendre S, Ellis R, Deutsch R, et al. Correlates of time-to-loss-of-viral- response in CSF and plasma in the CHARTER cohort. In: XVII Conference on Retroviruses and Opportunistic Infections (San Francisco). 2010 [abstract 430].
• ¹⁷
  Garvey L, Winston A, Walsh J, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology. 2011;76:693-700.
• ¹⁸
  McManus H, Li PC, Nolan D, et al. Does use of antiretroviral therapy regimens with high central nervous system penetration improve survival in HIV- infected adults? HIV Med. 2011;12:610-9.
• ¹⁹
  Gavegnano C, Schinazi RF. Antiretroviral therapy in macrophages: implication for HIV eradication. Antiviral Chem Chemother. 2009;20:63-78.
• ²⁰
  Kusao I, Shiramizu B, Liang CY, et al. Cognitive performance related to HIV-1-infected monocytes. J Neuropsychiatry Clin Neurosci. 2012;24:71-80.
• ²¹
  Gras G, Kaul M. Molecular mechanisms of neuroinvasion by monocytes- macrophages in HIV-1 infection. Retrovirology. 2010;7:30.
• ²²
  Kovalevich J, Langford D. Neuronal toxicity in HIV CNS disease. Future Virol. 2012;7:687-98.
• ²³
  Williams DW, Veenstra M, Gaskill PJ, Morgello S, Calderon TM, Berman JW. Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res. 2014;12:85-96.
• ²⁴
  Tavazzi E, Morrison D, Sullivan P, Morgello S, Fischer T. Brain inflammation is a common feature of HIV- infected patients without HIV encephalitis or productive brain infection. Curr HIV Res. 2014;12:97-110.
• ²⁵
  Shikuma CM, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012;17:1233-42.
• ²⁶
  Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS. 2005;19:1367-74.
• ²⁷
  Chaves ML, Ilha D, Maia AL, Motta E, Lehmen R, Oliveira LM. Diagnosing dementia and normal aging: clinical relevance of brain ratios and cognitive performance in a Brazilian sample. Braz J Med Biol Res. 1999;32:1133-43.
• ²⁸
  Dal Pan GJ, McArthur JH, Aylward E, et al. Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis. Neurology. 1992;42:2125-30.
• ²⁹
  Ragin AB, Du H, Ochs R, et al. Structural brain alterations can be detected early in HIV infection. Neurology. 2012;79:2328-34.
• ³⁰
  Pfefferbaum A, Rogosa DA, Rosenbloom MJ, et al. Accelerated aging of selective brain structures in human immunodeficiency virus infection: a controlled, longitudinal magnetic resonance imaging study. Neurobiol Aging. 2014;35:1755-68.
• ³¹
  Bonnet F, Amieva H, Marquant F, et al. Cognitive disorders in HIV- infected patients: are they HIV- related? AIDS. 2013;27:391-400.
• ³²
  Steinbrink F, Evers S, Buerke B, et al. Cognitive impairment in HIV infection is associated with MRI and CSF pattern of neurodegeneration. Eur J Neurol. 2013;20:420-8.
• ³³
  Gongvatana A, Harezlak J, Buchthal S, et al. Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. J Neurovirol. 2013;19:209-18.
• ³⁴
  Cysique LA, Moffat K, Moore DM, et al. HIV, vascular and aging injuries in the brain of clinically stable HIV- infected adults: a (1)H MRS study. PLoS ONE. 2013;8:e61738.
• ³⁵
  Patel SH, Kolson DL, Glosser G, et al. Correlation between percentage of brain parenchymal volume and neurocognitive performance in HIV- infected patients. Am J Neuroradiol. 2002;23:543-9.
• ³⁶
  Cusini A, Vernazza PL, Yerly S, et al. Higher CNS penetration- effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr. 2013;62:28-35.
• ³⁷
  Tozzi V, Balestra P, Salvatori MF, et al. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV- associated neurocognitive disorders. J Acquir Immune Defic Syndr. 2009;52:56-63.
• ³⁸
  Kahouadji Y, Dumurgier J, Sellier P, et al. Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. HIV Med. 2013;14:311-5.
• ³⁹
  Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359-66.
• ⁴⁰
  Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS. 2011;25:357-65.
• ⁴¹
  Ciccarelli N, Fabbiani M, Colafigli M, et al. Revised central nervous system neuropenetration- effectiveness score is associated with cognitive disorders in HIV- infected patients with controlled plasma viraemia. Antivir Ther. 2013;18:153-60.
• ⁴²
  Granziera C, Daducci A, Simioni S, et al. Micro- structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi- contrast study at high field. PLoS ONE. 2013;8:e72547.
• ⁴³
  Caniglia EC, Cain LE, Justice A, et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology. 2014;83:134-41.
• ⁴⁴
  Silverstein PS, Kumar S, Kumar A. HIV-1, HCV and alcohol in the CNS: potential interactions and effects on neuroinflammation. Curr HIV Res. 2014;12:282-92.
• ⁴⁵
  Smith DB, Simmonds P, Bell JE. Brain viral burden, neuroinflammation and neurodegeneration in HAART- treated HIV positive injecting drug users. J Neurovirol. 2014;20: 28-38.
• ⁴⁶
  Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV- infected patients. Neurology. 2011;76:1403-9.
• ⁴⁷
  Winston A, Arenas-Pinto A, Stöhr W, et al. Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS ONE. 2013;8:e61949.
• ⁴⁸
  Kumar A, Herbein G. The macrophage: a therapeutic target in HIV-1 infection. Mol Cell Ther. 2014;2:10.
• ⁴⁹
  Crommentuyn KML, Mulder JW, Mairuhu ATA, et al. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther. 2004;9:779-85.

• 2
  Appendix A. Supplementary data The following are the supplementary data to this article:

Publication Dates

• Publication in this collection
  Sep-Oct 2015

History

• Received
  27 Mar 2015
• Accepted
  06 July 2015